MCID: FRN031
MIFTS: 60

Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Mental diseases, Blood diseases

Aliases & Classifications for Frontotemporal Lobar Degeneration with Ubiquitin-Positive...

About this section
Sources:
11Disease Ontology, 12diseasecard, 26GTR, 29ICD10, 30ICD10 via Orphanet, 36MedGen, 39MESH via Orphanet, 47NIH Rare Diseases, 48NINDS, 49Novoseek, 51OMIM, 53Orphanet, 63The Human Phenotype Ontology, 67UMLS, 68UMLS via Orphanet, 69UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions:

Name: Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions 51
Aphasia, Primary Progressive 51 47 12
Primary Progressive Aphasia 47 48 67
Frontotemporal Lobar Degeneration with Tdp43 Inclusions, Grn-Related 51 67
Ubiquitin-Positive Frontotemporal Dementia 69 26
Primary Progressive Aphasia Syndrome 47 26
Grn-Related Frontotemporal Lobar Degeneration with Tdp43 Inclusions 11
Tau-Negative Frontotemporal Dementia Linked to Chromosome 17 69
Agramatic Variant of Primary Progressive Aphasia 53
Dementia, Hereditary Dysphasic Disinhibition 47
 
Frontotemporal Dementia, Ubiquitin-Positive 47
Progressive Non-Fluent Aphasia 53
Aphasia Primary Progressive 49
Agramatic Variant of Ppa 53
Frontotemporal Dementia 67
Non-Fluent Variant Ppa 53
Up-Ftd 69
Hddd 47
Ppa 47

Characteristics:

Orphanet epidemiological data:

53
agramatic variant of primary progressive aphasia:
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: Adult

HPO:

63
frontotemporal lobar degeneration with ubiquitin-positive inclusions:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM51 607485
Disease Ontology11 DOID:0060672
ICD1029 G31.0
Orphanet53 ORPHA100070
ICD10 via Orphanet30 G31.0
MESH via Orphanet39 D057178
UMLS via Orphanet68 C0751706

Summaries for Frontotemporal Lobar Degeneration with Ubiquitin-Positive...

About this section
OMIM:51 Clinically, FTLD-TDP is a type of frontotemporal dementia (see FTD; 600274) which shows variable phenotypic expression,... (607485) more...

MalaCards based summary: Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions, also known as aphasia, primary progressive, is related to semantic dementia and logopenic progressive aphasia, and has symptoms including Array, Array and Array. An important gene associated with Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions is GRN (Granulin Precursor), and among its related pathways are Alzheimers Disease Pathway and Neuroscience. Affiliated tissues include brain, testes and prefrontal cortex, and related mouse phenotypes are no phenotypic analysis and behavior/neurological.

Disease Ontology:11 A frontotemporal dementia characterized by variable phenotypic expression typically including social, behavioral, or language deterioration, rather than memory or motor deficits and the presence of TARDBP-positive inclusions that has material basis in mutation in the GRN gene on chromosome 17q21.31.

NIH Rare Diseases:47 Primary progressive aphasia (PPA) is a disorder characterized by language disturbance, including difficulty making or understanding speech (aphasia). In the early stages, PPA often causes difficulty with naming, word finding, or word comprehension. In later stages, affected people often become mute and lose their ability to communicate. PPA may sometimes be the initial manifestation of another neurodegenerative disease, such as frontotemporal dementia or Alzheimer disease. In some cases, PPA is caused by mutations in the GRN gene and is inherited in an autosomal dominant maner. PPA can be classified into three distinct types which include progressive non-fluent aphasia (PNFA), semantic dementia (SD), and the logopenic variant (LPA). Last updated: 9/10/2014

NINDS:48 Frontotemporal dementia (FTD) describes a clinical syndrome associated with shrinking of the frontal and temporal anterior lobes of the brain. Originally known as Pick?s disease, the name and classification of FTD has been a topic of discussion for over a century.

UniProtKB/Swiss-Prot:69 Ubiquitin-positive frontotemporal dementia: Frontotemporal dementia (FTD) is the second most common cause of dementia in people under the age of 65 years. It is an autosomal dominant neurodegenerative disease.

Related Diseases for Frontotemporal Lobar Degeneration with Ubiquitin-Positive...

About this section

Diseases related to Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 65)
idRelated DiseaseScoreTop Affiliating Genes
1semantic dementia11.8
2logopenic progressive aphasia11.6
3grn-related frontotemporal dementia11.5
4progressive non-fluent aphasia11.3
5dementia, frontotemporal11.1
6geleophysic dysplasia10.4GRN, PSEN1
7autoimmune disease of urogenital tract10.4GRN, PSEN1
8subdural empyema10.4PSEN1, TARDBP
9congenital hypoplastic anemia10.4PSEN1, TARDBP
10aphasia10.4
11fus-related amyotrophic lateral sclerosis10.4MAPT, PSEN1
12glucose metabolism disease10.4GRN, PSEN1
13suppurative thyroiditis10.4MAPT, TARDBP
14mecp2-related disorders10.4MAPT, PSEN1
15intravascular angioleiomyoma10.4GRN, PSEN1
16hyperglycemia10.3CHMP2B, GRN
17diffuse alopecia areata10.3GRN, PSEN1
18intracranial cavernous angioma10.3MAPT, PSEN1
19thryoid dyshormonogenesis 610.3MAPT, TARDBP
20simultanagnosia10.2GRN, PSEN1, TARDBP
21autotopagnosia10.2GRN, PSEN1, TARDBP
22central nervous system melanocytic neoplasm10.2TARDBP, VCP
23apraxia10.2GRN, PSEN1
24gingival disease10.1MAPT, RPS27A
25dementia10.1
26avoidant personality disorder10.1GRN, MAPT, PSEN1
27basilar impression, primary10.1MAPT, RPS27A
28microsporidiosis10.0MAPT, TARDBP
29anaerobic pneumonia10.0MAPT, PSEN1
30meier-gorlin syndrome 510.0GRN, MAPT, RPS27A
31osteogenesis imperfecta, type vi10.0C9orf72, TARDBP
32scrotal carcinoma10.0SQSTM1, VCP
33non-syndromic intellectual disability10.0SQSTM1, TARDBP, VCP
34polycystic kidney disease 210.0MAPT, RPS27A, SQSTM1
35childhood oligodendroglioma9.9C9orf72, TARDBP
36acrofrontofacionasal dysostosis9.9GRN, MAPT, PSEN1, TARDBP
37nasal cavity inverting papilloma9.9GRN, MAPT, PSEN1, TARDBP
38elephantiasis9.9GRN, MAPT, PSEN1, TARDBP
39parkinson disease 19.9GRN, MAPT, PSEN1, TARDBP
40adrenal gland pheochromocytoma9.9CHMP2B, MAPT, RPS27A
41fetal alcohol spectrum disorder9.7C9orf72, TARDBP
42carpenter syndrome9.7C9orf72, TREM2
43cardiomyopathy, dilated, 1u9.7MAPT, PSEN1, RPS27A, TARDBP
44neuromyotonia and axonal neuropathy, autosomal recessive9.5C9orf72, TARDBP, VCP
45perry syndrome9.5C9orf72, GRN, MAPT, TARDBP
46hypersensitivity syndrome, carbamazepine-induced9.5GRN, MAPT, PSEN1, SQSTM1, TARDBP
47parkinson disease, late-onset9.4MAPT, RPS27A, SQSTM1
48mast syndrome9.3C9orf72, MAPT, RPS27A, TARDBP
49atrophy of prostate9.3C9orf72, SQSTM1, TARDBP, VCP
50allergic bronchopulmonary aspergillosis, familial9.2MAPT, RPS27A, SQSTM1, TARDBP, VCP

Graphical network of the top 20 diseases related to Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions:



Diseases related to frontotemporal lobar degeneration with ubiquitin-positive inclusions

Symptoms for Frontotemporal Lobar Degeneration with Ubiquitin-Positive...

About this section

Symptoms by clinical synopsis from OMIM:

607485

Clinical features from OMIM:

607485

Human phenotypes related to Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions:

 53 63 (show all 46)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 thickened nuchal skin fold53 Very frequent (99-80%)
2 behavioral abnormality53 Occasional (29-5%)
3 restlessness53 Occasional (29-5%)
4 depression53 Frequent (79-30%)
5 anxiety53 Frequent (79-30%)
6 personality changes63 53 Occasional (29-5%) HP:0000751
7 mental deterioration53 Very frequent (99-80%)
8 stroke53 Excluded (0%)
9 parkinsonism63 53 Occasional (29-5%) HP:0001300
10 abnormality of extrapyramidal motor function53 Occasional (29-5%)
11 frontotemporal dementia63 53 Very frequent (99-80%) HP:0002145
12 neurofibrillary tangles53 Excluded (0%)
13 apraxia63 53 Frequent (79-30%) HP:0002186
14 mutism63 53 Occasional (29-5%) HP:0002300
15 memory impairment63 53 Very frequent (99-80%) HP:0002354
16 dysphasia63 53 Very frequent (99-80%) HP:0002357
17 abnormal lower motor neuron morphology53 Occasional (29-5%)
18 aphasia63 53 Very frequent (99-80%) HP:0002381
19 motor aphasia53 Occasional (29-5%)
20 astrocytosis53 Occasional (29-5%)
21 abnormality of the cerebral white matter53 Frequent (79-30%)
22 frontotemporal cerebral atrophy53 Very frequent (99-80%)
23 grammar-specific speech disorder53 Very frequent (99-80%)
24 temporal cortical atrophy53 Very frequent (99-80%)
25 alexia53 Frequent (79-30%)
26 dysgraphia53 Occasional (29-5%)
27 eeg with continuous slow activity53 Frequent (79-30%)
28 perseveration63 53 Occasional (29-5%) HP:0030223
29 abnormal brain fdg positron emission tomography53 Frequent (79-30%)
30 spoken word recognition deficit53 Very frequent (99-80%)
31 brain neoplasm53 Excluded (0%)
32 senile plaques53 Occasional (29-5%)
33 lewy bodies53 Excluded (0%)
34 hyperorality63 HP:0000710
35 agitation63 HP:0000713
36 disinhibition63 HP:0000734
37 hallucinations63 HP:0000738
38 apathy63 HP:0000741
39 cerebral cortical atrophy63 HP:0002120
40 gliosis63 HP:0002171
41 neuronal loss in central nervous system63 HP:0002529
42 polyphagia63 HP:0002591
43 dilation of lateral ventricles63 HP:0006956
44 progressive language deterioration63 HP:0007064
45 repetitive compulsive behavior63 HP:0008762
46 hypersexuality63 HP:0030214

UMLS symptoms related to Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions:


apathy, personality change, agitation, memory loss, restlessness

Drugs & Therapeutics for Frontotemporal Lobar Degeneration with Ubiquitin-Positive...

About this section

Drugs for Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 102)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CitalopramapprovedPhase 450359729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
2
Memantineapproved, investigationalPhase 4, Phase 3, Phase 217619982-08-24054
Synonyms:
1,3-Dimethyl-5-adamantanamine
1-Amino-3,5-dimethyladamantane
19982-08-2
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-adamantylamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyladamantan-1-ylamine
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
3,5-dimethyladamantan-1-amine
3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine
41100-52-1 (Hydrochloride)
51052-62-1
AB00053600
AC1L1HB7
AKOS000113995
BBL000737
BPBio1_001117
BPBio1_001270
BSPBio_001015
Biomol-NT_000209
C13736
CBMicro_020348
CHEBI:152523
CHEMBL807
CID4054
D08174
DB01043
DMAA
DivK1c_000068
EU-0053634
Ebixa
Exiba
Exiba (TN)
HMS500D10
HSDB 7327
IDI1_000068
KBio1_000068
KBio2_001087
KBio2_003655
 
KBio2_006223
KBio3_001926
KBioGR_001543
KBioSS_001087
LS-157051
Lopac0_000861
Memantin
Memantina
Memantina [INN-Spanish]
Memantine
Memantine (INN)
Memantine HCL
Memantine Hydrochloride
Memantine [INN:BAN]
Memantine [INN]
Memantinum
Memantinum [INN-Latin]
MolPort-002-041-858
NCGC00015705-05
NCGC00024782-02
NCGC00024782-03
NINDS_000068
Namenda
Oprea1_480562
Prestwick0_000978
Prestwick1_000978
Prestwick2_000978
Prestwick3_000978
SPBio_001456
SPBio_002926
ST057652
STK520682
Spectrum2_001408
Spectrum3_000923
Spectrum4_001022
Spectrum5_001355
Spectrum_000607
UNII-W8O17SJF3T
ZERO/006024
memantine
3
DopamineapprovedPhase 4, Phase 3, Phase 2, Phase 1375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
4
AmantadineapprovedPhase 467768-94-52130
Synonyms:
1-Adamantamine
1-Adamantanamine
1-Adamantanamine (8CI)
1-Adamantylamine
1-Aminoadamantane
1-Aminotricyclo(3.3.1.1(sup 3,7))decane
1-adamantanamine
1-adamantylamine
1-aminoadamantane
138576_ALDRICH
665-66-7 (hydrochloride)
768-94-5
AB00514655
AC-11992
AC1L1CZI
AC1Q4UAF
AC1Q5396
ADAMANTANE,1-AMINO
AKOS000113994
AKOS000119324
Adamantamine
Adamantanamine
Adamantylamine
Amant
Amantadina
Amantadina [INN-Spanish]
Amantadine
Amantadine (INN)
Amantadine Base
Amantadine HCL
Amantadine Hydrochloride
Amantadine [INN:BAN]
Amantadinum
Amantadinum [INN-Latin]
Amantidine
Ambap768-94-5
Aminoadamantane
BIA4304
BIDD:GT0757
BPBio1_000368
BRN 2204333
BSPBio_000334
BSPBio_001570
BSPBio_001822
Bio-0821
C06818
C10H17N
CHEBI:2618
CHEMBL660
CID2130
D07441
DB00915
DivK1c_000815
EINECS 212-201-2
Endantadine
Gen-Amantadine
HMS1791O12
HMS1989O12
HSDB 3202
I14-1101
IDI1_000815
InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H
KBio1_000815
KBio2_000390
 
KBio2_002958
KBio2_005526
KBio3_001322
KBioGR_000548
KBioSS_000390
L000868
LS-157049
Lopac-A-1260
Lopac0_000004
Mantadine
MolPort-001-661-700
MolPort-001-760-587
MolPort-001-791-102
NCGC00015036-01
NCGC00015036-07
NCGC00162039-01
NCGC00162039-02
NCGC00162039-03
NCGC00162039-04
NCGC00179597-01
NCIOpen2_001059
NINDS_000815
NSC 341865
NSC341865
NSC83653
OR14310
Oprea1_248648
Pk-Merz
Pk-merz
Prestwick0_000407
Prestwick1_000407
Prestwick2_000407
Prestwick3_000407
SPBio_000002
SPBio_002273
STK298781
Spectrum2_000081
Spectrum3_000291
Spectrum4_000134
Spectrum5_000772
Spectrum_000030
Symadine
Symmetrel
TCMDC-125869
TL8005280
Tricyclo(3.3.1.1(3,7))-decan-1-amine
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine
Tricyclo(3.3.1.1(sup 3.7))decan-1-amine
Tricyclo(3.3.1.13,7)decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-ylamine
Tricyclo[3.3.1.1(3,7)]decane-1-amine
Tricyclo[3.3.1.1(sup3,7)]decan-1-amine
Tricyclo[3.3.1.1^3,7]decan-1-amine
UNII-BF4C9Z1J53
Viregyt
Virosol
WLN: L66 B6 A B- C 1B ITJ BZ
Wiregyt
adamantan-1-amine
adamantan-1-ylamine
amantadine
amantadine hydrochloride
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
tricyclo[3.3.1.1(3,7)]decane-1-amine
tricyclo[3.3.1.1~3,7~]decan-1-amine
5Fluorodeoxyglucose F18Phase 4, Phase 2, Phase 1392
6Antiviral AgentsPhase 4, Phase 3, Phase 1, Phase 29732
7Serotonin Uptake InhibitorsPhase 41570
8Peripheral Nervous System AgentsPhase 4, Phase 222776
9Antiparkinson AgentsPhase 4, Phase 3, Phase 21527
10Anti-Infective AgentsPhase 4, Phase 3, Phase 1, Phase 221402
11
CorticosteronePhase 4, Phase 1, Early Phase 11150-22-65753
Synonyms:
11,21-Dihydroxypregn-4-ene-3,20-dione
11,21-Dihydroxyprogesterone
11-Hydroxycorticoaldosterone
 
17-Deoxycortisol
4-Pregnene-11 Corticosteron
Corticosterone
Kendall'S compound B
Reichstein'S substance H
12Serotonin AgentsPhase 43102
13Neurotransmitter Uptake InhibitorsPhase 43464
14Excitatory Amino AcidsPhase 4, Phase 3, Phase 21297
15Excitatory Amino Acid AntagonistsPhase 4, Phase 3, Phase 21282
16Dopamine AgentsPhase 4, Phase 3, Phase 2, Phase 13759
17
SerotoninPhase 4356650-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
18Neurotransmitter AgentsPhase 4, Phase 3, Phase 217734
19Psychotropic DrugsPhase 4, Phase 26279
20Antidepressive Agents, Second-GenerationPhase 41287
21Antidepressive AgentsPhase 4, Phase 22666
22Pharmaceutical SolutionsPhase 4, Phase 2, Phase 3, Phase 17793
23
IodinePhase 45467553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
24cadexomer iodinePhase 4514
25Anti-Inflammatory AgentsPhase 410355
26AnalgesicsPhase 411287
27Analgesics, Non-NarcoticPhase 46260
28CalamusNutraceuticalPhase 4419
29
Busulfanapproved, investigationalPhase 2, Phase 354055-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
30
Cyclophosphamideapproved, investigationalPhase 2, Phase 3282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
31
MiglustatapprovedPhase 3, Phase 2, Phase 12172599-27-051634
Synonyms:
(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
1,5-Dideoxy-1,5-N-butylimino-D-glucitol
134282-77-2
72599-27-0
AC1L1BHJ
BuDNJ
Butyldeoxynojirimycin
CHEBI:49779
CHEBI:50381
CHEMBL1029
CID51634
D05032
DB00419
HMS2090N20
LS-116261
Miglustat
Miglustat (USAN/INN)
Miglustat [USAN]
Miglustat, Hydrochloride
Miglustatum
N-(N-Butyl)deoxynojirimycin
N-(n-Butyl)deoxynojirimycin
N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol
 
N-Bu-DNJ
N-Butyl deoxynojirimycin
N-Butyl-1-deoxynojirimycin
N-Butyl-DNJ
N-Butyl-deoxynojirimycin
N-Butyldeoxynojirimycin
N-Butylmoranoline
N-butyl-1-deoxynojirimycin
NB-DNJ
NB-dnj
NBV
OGT 918
OGT-918
SC 48334
SC-48334
SC48334
UNII-ADN3S497AZ
Vevesca
Zavesca
Zavesca (TN)
miglustatum
n-Butyl deoxynojirimycin
n-Butyl dnj
nchembio.81-comp12
nchembio850-comp5
32
BenzocaineapprovedPhase 318921994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
33
Prednisoloneapproved, vet_approvedPhase 2, Phase 3115350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
34
Methylprednisoloneapproved, vet_approvedPhase 2, Phase 3115383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
35tannic acidapproved, NutraceuticalPhase 31892
36
1-DeoxynojirimycinexperimentalPhase 3, Phase 22619130-96-21374
Synonyms:
(2R,3R,4R,5S)-2-(Hydroxymethyl)piperidine-3,4,5-triol
1 deoxynojirimycin
1,5-Dideoxy-1,5-imino-D-glucitol, 9CI
1,5-deoxy-1,5-imino-D-mannitol
1,5-dideoxy-1,5-imino-D-glucitol
1-DEOXY-NOJIRIMYCIN
1-Deoxymannojirimycin
1-Deoxynojirimycin
1-Deoxynojirimycin (DNJ)
1-deoxy-nojirimycin
 
1-deoxynojirimycin
1hxk
1oim
5-amino-1,5-dideoxy-D-glucopyranose
Antibiotic S-GI
D-1-deoxynojirimycin
DNJ
Deoxynojirimycin
Moranoline
NOJ
S-GI
37Immunosuppressive AgentsPhase 2, Phase 312770
38Prednisolone hemisuccinatePhase 2, Phase 31153
39Prednisolone acetatePhase 2, Phase 31153
40Methylprednisolone HemisuccinatePhase 2, Phase 31153
41Methylprednisolone acetatePhase 2, Phase 31153
42Prednisolone phosphatePhase 2, Phase 31153
43Anti-Retroviral AgentsPhase 3, Phase 2, Phase 13232
44Anti-HIV AgentsPhase 3, Phase 2, Phase 13100
45Antirheumatic AgentsPhase 2, Phase 310627
46Glycoside Hydrolase InhibitorsPhase 3, Phase 2, Phase 1128
47Cardiac GlycosidesPhase 3, Phase 2, Phase 1148
48Antilymphocyte SerumPhase 2, Phase 3399
49Alkylating AgentsPhase 2, Phase 34694
50Antineoplastic Agents, AlkylatingPhase 2, Phase 34474

Interventional clinical trials:

(show top 50)    (show all 131)
idNameStatusNCT IDPhase
1Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal DementiaCompletedNCT00545974Phase 4
2Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal DementiaCompletedNCT00376051Phase 4
3Imaging of Brain Amyloid Plaques in the Aging PopulationEnrolling by invitationNCT00950430Phase 4
4DaTSCAN Imaging in Aging and Neurodegenerative DiseaseEnrolling by invitationNCT01453127Phase 4
5Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)TerminatedNCT00127114Phase 4
6Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)CompletedNCT01626378Phase 3
7Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal DementiaCompletedNCT00594737Phase 3
8Application of Miglustat in Patients With Niemann-Pick Type CCompletedNCT01760564Phase 3
9Stem Cell Transplant for Inborn Errors of MetabolismCompletedNCT00176904Phase 2, Phase 3
10Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type CRecruitingNCT02612129Phase 2, Phase 3
11Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) DiseaseRecruitingNCT02534844Phase 2, Phase 3
12Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase DeficiencyRecruitingNCT02004691Phase 2, Phase 3
13SurVival of Lysosomal Acid Lipase Deficiency (LAL-D) Infants Treated With SebelipAse aLfaActive, not recruitingNCT01371825Phase 2, Phase 3
14Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)Enrolling by invitationNCT02245568Phase 3
15ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic DiseasesTerminatedNCT00654433Phase 3
16Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102TerminatedNCT01473875Phase 2, Phase 3
17Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1CompletedNCT02124083Phase 1, Phase 2
18A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal DementiaCompletedNCT00416169Phase 2
19Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl CysteineCompletedNCT00975689Phase 1, Phase 2
20Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) PatientsCompletedNCT00200538Phase 2
21Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.CompletedNCT01890343Phase 2
22Electroencephalography (EEG) Biofeedback Training to Improve Executive Functioning and Memory in Adults With a Dementing IllnessCompletedNCT01168466Phase 2
23Double Blind Trial of DC Polarization in FTDCompletedNCT00117858Phase 2
24Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood CellsCompletedNCT00730314Phase 1, Phase 2
25Miglustat in Niemann-Pick Type C DiseaseCompletedNCT00517153Phase 2
26Impact of Emotional Mimicry and Oxytocin on Frontotemporal DementiaRecruitingNCT01937013Phase 2
27Safety, Tolerability and Efficacy of AVP-786 for the Treatment of DisinhibitionRecruitingNCT02534038Phase 2
28F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral SclerosisRecruitingNCT02414230Phase 2
29Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase DeficiencyRecruitingNCT02292654Phase 1, Phase 2
30A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase DeficiencyRecruitingNCT02004704Phase 2
31Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin MutationActive, not recruitingNCT02149160Phase 2
32Effects of Tolcapone on Frontotemporal DementiaActive, not recruitingNCT00604591Phase 2
33Davunetide (AL-108) in Predicted Tauopathies - Pilot StudyActive, not recruitingNCT01056965Phase 2
34Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic DisordersActive, not recruitingNCT01372228Phase 1, Phase 2
35Clinical Trial in Infants With Rapidly Progressive Lysosomal Acid Lipase DeficiencyActive, not recruitingNCT02193867Phase 2
36Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT MutationsEnrolling by invitationNCT02676843Phase 2
37Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal DementiaNot yet recruitingNCT02862210Phase 2
38Study of Pharmacokinetics and Preliminary Efficacy in Patients With Niemann-Pick C1Not yet recruitingNCT02912793Phase 1, Phase 2
39F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)Not yet recruitingNCT02707978Phase 2
40Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of MetabolismTerminatedNCT00668564Phase 2
41Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal DementiaUnknown statusNCT00674960Phase 1
42Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive ImpairmentUnknown statusNCT00149175Phase 1
43Far Infrared Radiation Treatment of Dementia and Other Mental IllnessUnknown statusNCT00574054Phase 1
44Safety Study of Intranasal Oxytocin in Frontotemporal DementiaCompletedNCT01386333Phase 1
45Direct Current Brain Polarization in Frontotemporal DementiaCompletedNCT00077896Phase 1
46Saccadic Eye Movements in Patients With Niemann-Pick Type C DiseaseCompletedNCT00316498Phase 1
47Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical ADCompletedNCT01723553Phase 1
48Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene MutationsCompletedNCT01835665Phase 1
49Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy SubjectsCompletedNCT02103894Phase 1
50PiB PET Scanning in Speech and Language Based DementiasCompletedNCT01623284Phase 1

Search NIH Clinical Center for Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions

Genetic Tests for Frontotemporal Lobar Degeneration with Ubiquitin-Positive...

About this section

Genetic tests related to Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions:

id Genetic test Affiliating Genes
1 Frontotemporal Dementia, Ubiquitin-Positive26
2 Primary Progressive Aphasia26

Anatomical Context for Frontotemporal Lobar Degeneration with Ubiquitin-Positive...

About this section

MalaCards organs/tissues related to Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions:

35
Brain, Testes, Prefrontal cortex, Skin, Cortex, Bone, Eye

Animal Models for Frontotemporal Lobar Degeneration with Ubiquitin-Positive... or affiliated genes

About this section

MGI Mouse Phenotypes related to Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00030128.5C9orf72, GRN, MAPT, TARDBP, TREM2
2MP:00053868.4C9orf72, GRN, MAPT, PSEN1, SQSTM1, TARDBP
3MP:00053848.4C9orf72, GRN, MAPT, PSEN1, SQSTM1, TARDBP
4MP:00053978.4C9orf72, GRN, MAPT, PSEN1, SQSTM1, TARDBP
5MP:00053878.0C9orf72, GRN, MAPT, PSEN1, SQSTM1, TARDBP
6MP:00036317.9C9orf72, CHMP2B, GRN, MAPT, PSEN1, SQSTM1

Publications for Frontotemporal Lobar Degeneration with Ubiquitin-Positive...

About this section

Articles related to Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions:

idTitleAuthorsYear
1
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry. (18379439)
2008
2
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. (17278999)
2007
3
Frontotemporal lobar degeneration with ubiquitin-positive inclusions: a molecular genetic update. (17596717)
2007
4
Appearance pattern of TDP-43 in Japanese frontotemporal lobar degeneration with ubiquitin-positive inclusions. (17507161)
2007
5
Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations. (17353379)
2007
6
TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. (17356379)
2007
7
Neuropathologic heterogeneity in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation. (17334266)
2007
8
TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions. (17923628)
2007
9
Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. (17003490)
2006

Variations for Frontotemporal Lobar Degeneration with Ubiquitin-Positive...

About this section

UniProtKB/Swiss-Prot genetic disease variations for Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions:

69
id Symbol AA change Variation ID SNP ID
1GRNp.Ala9AspVAR_044451rs63751243

Clinvar genetic disease variations for Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions:

5 (show all 42)
id Gene Variation Type Significance SNP ID Assembly Location
1MAPTNM_016835.4(MAPT): c.1853C> T (p.Pro618Leu)SNVPathogenicrs63751273GRCh37Chr 17, 44087755: 44087755
2MAPTNM_016835.4(MAPT): c.1766G> T (p.Gly589Val)SNVPathogenicrs63750376GRCh37Chr 17, 44074023: 44074023
3MAPTNM_016835.4(MAPT): c.2167C> T (p.Arg723Trp)SNVPathogenicrs63750424GRCh37Chr 17, 44101427: 44101427
4MAPTNM_016835.4(MAPT): c.1866+14C> TSNVPathogenicrs63750972GRCh37Chr 17, 44087782: 44087782
5MAPTMAPT, IVS10, A-G, +13SNVPathogenicChr na, -1: -1
6MAPTMAPT, IVS10, C-T, +16SNVPathogenicChr na, -1: -1
7MAPTMAPT, IVS10, G-A, +1SNVPathogenicChr na, -1: -1
8MAPTNM_016835.4(MAPT): c.1960G> A (p.Val654Met)SNVPathogenicrs63750570GRCh37Chr 17, 44095995: 44095995
9MAPTNM_016835.4(MAPT): c.1788T> G (p.Asn596Lys)SNVPathogenicrs63750756GRCh37Chr 17, 44087690: 44087690
10MAPTNM_016835.4(MAPT): c.1865G> A (p.Ser622Asn)SNVPathogenicrs63751165GRCh37Chr 17, 44087767: 44087767
11MAPTNM_016835.4(MAPT): c.1852C> T (p.Pro618Ser)SNVPathogenicrs63751438GRCh37Chr 17, 44087754: 44087754
12MAPTNM_016835.4(MAPT): c.1839T> C (p.Asn613=)SNVPathogenicrs63750912GRCh37Chr 17, 44087741: 44087741
13MAPTNM_016835.4(MAPT): c.1976A> T (p.Glu659Val)SNVPathogenicrs63750711GRCh37Chr 17, 44096011: 44096011
14MAPTNM_005910.5(MAPT): c.14G> A (p.Arg5His)SNVPathogenicrs63750959GRCh37Chr 17, 44039717: 44039717
15MAPTMAPT, IVS10, T-C, +11SNVPathogenicChr na, -1: -1
16MAPTNM_016835.4(MAPT): c.1747C> G (p.Leu583Val)SNVPathogenicrs63750349GRCh37Chr 17, 44074004: 44074004
17MAPTNM_016835.4(MAPT): c.1901A> T (p.Lys634Met)SNVPathogenicrs63750092GRCh37Chr 17, 44091643: 44091643
18GRNGRN, IVS0, G-C, +5SNVPathogenicChr na, -1: -1
19GRNNM_002087.3(GRN): c.373C> T (p.Gln125Ter)SNVPathogenicrs63750077GRCh37Chr 17, 42427619: 42427619
20GRNNM_002087.3(GRN): c.2T> C (p.Met1Thr)SNVPathogenicrs63751006GRCh37Chr 17, 42426534: 42426534
21GRNNM_002087.3(GRN): c.3G> A (p.Met1Ile)SNVPathogenicrs63750331GRCh37Chr 17, 42426535: 42426535
22GRNNM_002087.3(GRN): c.93_96dupCCTG (p.Asp33Profs)duplicationPathogenicrs606231220GRCh38Chr 17, 44349257: 44349260
23GRNNM_002087.3(GRN): c.388_391delCAGT (p.Gln130Serfs)deletionPathogenicrs63749801GRCh37Chr 17, 42427634: 42427637
24GRNNM_002087.3(GRN): c.835+1G> ASNVPathogenicrs606231221GRCh38Chr 17, 44351164: 44351164
25GRNNM_002087.3(GRN): c.26C> A (p.Ala9Asp)SNVPathogenicrs63751243GRCh37Chr 17, 42426558: 42426558
26GRNNM_002087.3(GRN): c.1477C> T (p.Arg493Ter)SNVPathogenicrs63751294GRCh37Chr 17, 42429772: 42429772
27GRNGRN, 1-BP DEL, 998GdeletionPathogenicChr na, -1: -1
28GRNGRN, 1-BP INS, 1145AinsertionPathogenicChr na, -1: -1
29GRNGRN, IVS7AS, A-G, -2SNVPathogenicChr na, -1: -1
30GRNGRN, 2-BP DEL, 675CAdeletionPathogenicChr na, -1: -1
31GRNGRN, IVS6AS, A-G, -2SNVPathogenicChr na, -1: -1
32GRNNM_002087.3(GRN): c.813_816delCACT (p.Thr272Serfs)deletionPathogenicrs63749877GRCh37Chr 17, 42428509: 42428512
33GRNGRN, 1-BP DEL, 102CdeletionPathogenicChr na, -1: -1
34GRNGRN, 1-BP DEL, 154AdeletionPathogenicChr na, -1: -1
35PSEN1NM_000021.3(PSEN1): c.338T> C (p.Leu113Pro)SNVPathogenicrs63751399GRCh37Chr 14, 73637755: 73637755
36GRNNM_002087.3(GRN): c.462+1G> CSNVPathogenicrs794729669GRCh37Chr 17, 42427709: 42427709
37GRNNM_002087.3(GRN): c.882T> G (p.Tyr294Ter)SNVPathogenicrs794729670GRCh37Chr 17, 42428777: 42428777
38GRNNM_002087.3(GRN): c.1212C> A (p.Cys404Ter)SNVPathogenicrs193026789GRCh37Chr 17, 42429415: 42429415
39GRNNM_002087.3(GRN): c.1246dupT (p.Cys416Leufs)duplicationPathogenicrs794729671GRCh37Chr 17, 42429449: 42429449
40GRNNM_002087.3(GRN): c.87dupC (p.Cys30Leufs)duplicationPathogenicrs794729672GRCh37Chr 17, 42426619: 42426619
41GRNNM_002087.3(GRN): c.708+1G> ASNVPathogenicrs63749817GRCh37Chr 17, 42428169: 42428169
42GRNGRN, IVS6AS, G-A, -1SNVPathogenicChr na, -1: -1

Expression for genes affiliated with Frontotemporal Lobar Degeneration with Ubiquitin-Positive...

About this section
Search GEO for disease gene expression data for Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions.

Pathways for genes affiliated with Frontotemporal Lobar Degeneration with Ubiquitin-Positive...

About this section

Pathways related to Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.9MAPT, PSEN1
29.0MAPT, PSEN1, TARDBP, TREM2

GO Terms for genes affiliated with Frontotemporal Lobar Degeneration with Ubiquitin-Positive...

About this section

Cellular components related to Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1aggresomeGO:00162359.9PSEN1, SQSTM1
2cytoplasmic vesicleGO:00314109.1C9orf72, PSEN1, SQSTM1

Biological processes related to Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1positive regulation of dendritic spine developmentGO:006099910.0GRN, PSEN1
2error-free translesion synthesisGO:00709879.7RPS27A, VCP
3translesion synthesisGO:00199859.7RPS27A, VCP
4viral life cycleGO:00190589.5CHMP2B, RPS27A
5endosomal transportGO:00161978.6CHMP2B, RPS27A, SQSTM1
6autophagyGO:00069148.3C9orf72, CHMP2B, PSEN1, SQSTM1, VCP

Sources for Frontotemporal Lobar Degeneration with Ubiquitin-Positive...

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet